Bone Broth Protein Pharma Grade API is released as a low-molecular-weight collagen hydrolysate derived from bovine bone broth and is assigned two manufacturer product codes: BBP-PG-100 for oral solid and granulated dosage forms, and BBP-PG-200-INJ for injectable formulations. The material is supplied as a spray-dried powder with total protein by Kjeldahl nitrogen ×6.25 controlled to 90.0–95.0% w/w for the oral grade and 92.0–97.0% w/w for the injectable grade. The oral grade is used in tablet, capsule, and granule manufacture; the injectable grade is intended for reconstituted solution or lyophilized cake production. Regulatory classification as an active substance or as an excipient must be established under the applicable registration pathway because bone broth protein hydrolysate does not have a harmonized pharmacopoeial monograph. The following release profile applies to both product codes. Product code assignments are manufacturer identifiers and do not denote compendial status.

Compendial Alignment Begins with Source Tissue Control

Bovine bone tissue is sourced from closed herds with documented veterinary health records and specified risk material exclusion. Incoming tissue is held at −20 °C until extraction. Demineralization is executed with dilute hydrochloric acid at pH 2.0–3.0, followed by neutralization and thermal hydrolysis at 90–95 °C for 6–8 h. The hydrolysis vessel is equipped with continuous temperature and pH recording; a deviation of more than ±2 °C from the target temperature requires batch quarantine. The crude hydrolysate is clarified through a 0.5–1.0 µm depth filter and polished through 0.45 µm membrane before spray drying. Spray drying inlet air temperature is maintained at 160–180 °C with outlet temperature 75–85 °C; outlet temperature above 90 °C is associated with increased insoluble particulate and darkening. Bioburden is limited to ≤10² CFU/g by Ph. Eur. 2.6.12, and specified pathogens are absent per Ph. Eur. 2.6.13. Residual ethanol, acetone, and isopropanol are limited as Class 3 solvents by Ph. Eur. 2.4.24. Viral safety is supported by animal health screening and by the thermal hydrolysis step; however, the process does not include a dedicated viral inactivation step, so downstream sterile filtration or viral filtration may be required for injectable products.

What Distinguishes Pharma-Grade Bone Broth Protein from Food-Grade Hydrolysates?

The pharmaceutical product is separated from food-grade bone broth powders by controlled molecular weight, reduced bioburden, endotoxin testing, and residual solvent control. Food-grade bone broth powders typically exhibit broad and variable peptide distribution and may contain added sodium chloride, maltodextrin, yeast extract, or flavoring. The pharma-grade oral product is non-gelling and remains soluble in cold water at 10% w/w, producing turbidity below 20 NTU for oral grade and below 10 NTU for injectable grade. By contrast, gelatin derived from bone or hide retains a high-molecular-weight fraction above 100 kDa and forms thermoreversible gels at 1–2% w/w after cooling. The peptide profile of the pharma-grade hydrolysate centers between 2.0 kDa and 5.0 kDa, with the injectable grade ultrafiltered to remove aggregates and endotoxin. This distinction has direct formulation consequences: the hydrolysate can be used as a water-soluble protein component in immediate-release tablets, granules, and oral solutions, whereas gelatin is used as a capsule shell, coating, or plasma expander.

The amino acid profile is dominated by glycine, proline, hydroxyproline, alanine, and glutamic acid. Routine amino acid analysis by Ph. Eur. 2.2.56 reports glycine 20–25 g/100 g protein, proline 10–15 g/100 g, hydroxyproline 8–12 g/100 g, alanine 7–10 g/100 g, and glutamic acid 8–11 g/100 g. Tryptophan is typically not detected, and cysteine is present only in low amounts; therefore, the product should not be used as the sole source of indispensable amino acids in parenteral nutrition without supplementation.

Powder Rheology and Direct Compression Behavior

Bulk density and tapped density are measured by USP <616>. The oral grade has bulk density 0.25–0.35 g/mL and tapped density 0.35–0.50 g/mL; Hausner ratio is 1.25–1.45, indicating passable to poor flow. A direct-compression variant, BBP-PG-100-DC, is densified to tapped density 0.40–0.50 g/mL and Hausner ratio 1.15–1.25. Particle size is measured by laser diffraction using ISO 13320:2020, with D10 10–25 µm, D50 45–75 µm, and D90 ≤150 µm for the oral grade. The fine fraction below 10 µm is controlled below 10% to reduce dusting and punch sticking. For direct compression, BBP-PG-100 is typically blended with microcrystalline cellulose, croscarmellose sodium, and 0.5–1.0% w/w magnesium stearate. The lubricant should be added last and blended for 3–5 min at 25 rpm in a bin blender; longer lubrication can reduce tablet tensile strength and delay disintegration beyond 15 min evaluated by Ph. Eur. 2.9.1 in 900 mL water at 37 °C. On a 16-station rotary press at 650 mg target tablet weight and 30% w/w BBP-PG-100, compression force 8–14 kN typically produces hardness 80–120 N. These values are press-specific; published data for this exact formulation is limited and compaction simulation is recommended.

Capsule filling on a dosator machine may require 0.5% w/w fumed silicon dioxide or pre-compacted granules; without glidant, fill weight variation can exceed 5% RSD at dosator nozzles below 2 mm. For low-dose formulations, pre-blending with lactose monohydrate or microcrystalline cellulose in a geometric dilution sequence is recommended because the peptide powder tends to segregate from free-flowing diluents if the particle size ratio exceeds 3:1. Dry granulation on a twin-screw roller compactor with roll diameter 120 mm, gap 1.5–2.0 mm, and roll force 8–12 kN/cm produces ribbons with solid fraction 0.62–0.68; milled granules with D50 200–400 µm are suitable for subsequent tableting. Wet granulation is performed in a high-shear granulator with impeller speed 300–500 rpm and chopper 1500 rpm, using purified water or 20% v/v ethanol. Impeller torque should reach 1.2–1.5 times the dry-blend baseline before discharge; overgranulation leads to dense granules with prolonged disintegration above 15 min and reduced dissolution plateau. Fluid-bed drying inlet air temperature should not exceed 60 °C, because higher temperatures increase the insoluble fraction and produce turbidity above 20 NTU after reconstitution. Materials stored outside sealed aluminum-laminated bags at relative humidity above 60% RH require pre-drying at 40 °C for 2–4 h before compression. Avoid dry blending with strong oxidizing agents, aldehydes, or reducing sugars; Maillard-type degradation can accelerate if moisture and heat are present.

For oral liquid and dispersible preparations, the oral grade is reconstituted in purified water at 10% w/v; viscosity remains below 10 mPa·s at 25 °C when measured by rotational viscometer at 50 s⁻¹. This permits peristaltic pumping and filling on standard liquid lines. Concentrations up to 15% w/v may be achieved with stirred mixing at 40 °C; at higher concentrations, foam formation complicates filling and the solution may phase-separate if pH falls below 3.5. Use a vacuum deaerator equipped with 0.1 MPa vacuum to reduce trapped air after dissolving the oral grade. Preserved solutions require preservative efficacy testing according to Ph. Eur. 5.1.3.

When Injectable-Grade Requirements Dictate Ultrafiltration and Endotoxin Control

The injectable product is ultrafiltered through 5 kDa and 3 kDa polyethersulfone membranes to reduce high-molecular-weight aggregates and endotoxin. The bulk solution is then passed through 0.22 µm PVDF or PES membrane filters. Bacterial endotoxin release limit is ≤0.5 EU/mg by Ph. Eur. 2.6.14. Osmolality of a 10% w/v injectable-grade solution is approximately 150–250 mOsm/kg, requiring tonicity adjustment with sodium chloride or mannitol to 270–320 mOsm/kg by Ph. Eur. 2.2.35. pH adjustment may be performed with diluted hydrochloric acid or sodium hydroxide; target pH is 6.0–7.0. Subvisible particulate matter for the reconstituted injection is evaluated by Ph. Eur. 2.9.19; acceptance criteria should be consistent with the target route and container volume. For small-volume injectables, harmonized limits are ≤6000 particles per container for ≥10 µm and ≤600 for ≥25 µm, but limits vary by volume and route. Bacterial endotoxin testing alone does not satisfy all non-endotoxin pyrogen requirements; rabbit pyrogen testing by Ph. Eur. 2.6.8 may be required for injectable products if the route or dose dictates.

Terminal sterilization by autoclaving above 121 °C is not recommended because heat-induced aggregation can increase turbidity and produce visible particulates. Aseptic filtration and aseptic filling are the preferred operations. The filtered solution should not be held for more than 4 h at 20–25 °C before filling unless hold-time validation demonstrates acceptable bioburden. For lyophilized cakes, 2–5% w/w trehalose or mannitol may be used as a bulking agent; reconstitution with sterile water for injection should produce a clear to slightly opalescent solution within 2 min with manual swirling. Avoid combination with formaldehyde-releasing preservatives, benzalkonium chloride at acidic pH below 3.5, or strong oxidizing agents. Published data for this specific injection configuration is limited; product-specific filter compatibility and extractable studies are required before commercial batch release.

Both product codes are packaged in double polyethylene liners inside aluminum-laminated bags with desiccant. Recommended storage is 15–25 °C and ≤35% RH. Under these conditions, the manufacturer assigns a retest interval of 24 months for BBP-PG-100 and 18 months for BBP-PG-200-INJ. Opened containers should be resealed under nitrogen and used within 30 days; prolonged exposure to ambient humidity above 60% RH may increase loss on drying and reduce flowability.